Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 201–300 of 879
Dhliwayo, N., Sarras, M. P., Luczkowski, E., Mason, S. M., & Intine, R. V. A. (2014) · Diabetes · doi:10.2337/db13-1916 · Cited by 67
Food and Western Disease Health and Nutrition from an Evolutionary Perspective
Lindeberg, S. (2009) · Cited by 64
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 70
Simmons, R. K., Unwin, N. C., & Griffin, S. J. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.003 · Cited by 76
Strategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
Diabetes Diagnosis and Control: Missed Opportunities to Improve Health
Cowie, C. C. (2019) · Diabetes Care · doi:10.2337/dci18-0047 · Cited by 68
Prato, S. D., LaSalle, J. R., Matthaei, S., Bailey, C. J., & Management, O. B. O. T. G. P. F. E. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02227.x · Cited by 66
Tu, S., Chang, S.-J., Chen, J.-F., Tien, K.-J., Hsiao, J.-Y., Chen, H.-C., & Hsieh, M.-C. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.471 · Cited by 63
Lee, S. J., Boscardin, W. J., Cenzer, I. S., Huang, E. S., Rice‐Trumble, K., & Eng, C. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03362.x · Cited by 69
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 68
Clinical Implications of the ACCORD Trial
Genuth, S., & Ismail-Beigi, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 56
Selecting an A1C Point-of-Care Instrument
Whitley, H. P., Yong, E. V., & Rasinen, C. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.201 · Cited by 59
Alwafi, H. H., Alsharif, A. A., Wei, L., Langan, D., Naser, A. Y., Mongkhon, P., Bell, J. S., Ilomäki, J., AlMetwazi, M. S., Man, K. K. C., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108522 · Cited by 60
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Need for better diabetes treatment for improved renal outcome
Rossing, P. R., & de Zeeuw, D. (2011) · Kidney International · doi:10.1038/ki.2010.513 · Cited by 60
HbA1c and all-cause mortality risk among patients with type 2 diabetes
Li, W., Katzmarzyk, P. T., Horswell, R., Wang, Y., Johnson, J., & Hu, G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.070 · Cited by 53
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
Sharrief, A. Z., & Grotta, J. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00021-2 · Cited by 70
Impact of lifestyle modification on glycemic control in patients with type 2 diabetes mellitus
Sanghani, N. B., Parchwani, D. N., Palandurkar, K. M., Shah, A. M., & Dhanani, J. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.122618 · Cited by 72
Targeted learning in real‐world comparative effectiveness research with time‐varying interventions
Neugebauer, R. S., Schmittdiel, J. A., & van der Laan, M. J. (2014) · Statistics in Medicine · doi:10.1002/sim.6099 · Cited by 60
Lin, J., Zhou, S., Wei, W., Pan, C., Lingohr-Smith, M., & Levin, P. (2016) · Endocrine Practice · doi:10.4158/ep15868.or · Cited by 52
Pérez, A., Franch‐Nadal, J., Cases, A., González‐Juanatey, J. R., Conthe, P., Gimeno, E., & Matalí, A. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.06.026 · Cited by 52
Vascular Calcification in Diabetes: Mechanisms and Implications
Snell‐Bergeon, J. K., Budoff, M. J., & Hokanson, J. E. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0379-7 · Cited by 56
Göbl, C. S., Brannath, W., Bozkurt, L., Handisurya, A., Anderwald, C. H., Luger, A., Krebs, M., Kautzky‐Willer, A., & Bischof, M. G. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.11.003 · Cited by 53
Algorithms of Specialized Medical Care for Diabetes Mellitus Patients
Dedov, I. I., Shestakova, M. V., Александров, А. А., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Kuraeva, T. L., Lipatov, D. V., Mayorov, A. Y., et al. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-5612 · Cited by 53
Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Transition From Intravenous to Subcutaneous Insulin
Avanzini, F., Marelli, G., Donzelli, W., Busi, G., Carbone, S., Bellato, L., Colombo, E. L., Foschi, R., Riva, E., Roncaglioni, M. C., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2023 · Cited by 50
Mannucci, E., & Monami, M. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0432-4 · Cited by 49
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 51
Hinzmann, R., Schlaeger, C., & Tran, C. T. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4520 · Cited by 62
Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
Norhammar, A., Mellbin, L., & Cosentino, F. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317709554 · Cited by 49
Kim, K. J., Choi, J., Bae, J. H., Kim, K. J., Yoo, H. J., Seo, J. A., Kim, N. H., Choi, K. M., Baik, S. H., Kim, S. G., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0046 · Cited by 58
Mannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Self-citationTkáč, I. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70011-7 · Cited by 55
Cardiovascular Benefits of Exogenous Insulin
Chaudhuri, A., Dandona, P., & Fonseca, V. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1112 · Cited by 47
Kim, H., Kim, D. M., Cha, B., Park, T. S., Kim, K., Kim, D., Chung, C. H., Park, J., Jang, H. C., & Choi, D.-S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12201 · Cited by 60
Esposito, K., Mosca, C., Brancario, C., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.590127 · Cited by 47
Namba, M., Iwakura, T., Nishimura, R., Akazawa, K., Matsuhisa, M., Atsumi, Y., Satoh, J., & Yamauchi, T. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12790 · Cited by 52
(Anti)Fragility and Convex Responses in Medicine
Taleb, N. N. (2018) · Springer proceedings in complexity · doi:10.1007/978-3-319-96661-8_32 · Cited by 50
Nichols, G. A., Joshua-Gotlib, S., & Parasuraman, S. V. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2320-1 · Cited by 48
Exercise in Cardiovascular Diseases
Pérez-Terzic, C. M. (2012) · PM&R · doi:10.1016/j.pmrj.2012.10.003 · Cited by 57
Insulin Detemir: A Review of its Use in the Management of Diabetes Mellitus
Keating, G. M. (2012) · Drugs · doi:10.2165/11470200-000000000-00000 · Cited by 56
Kesavadev, J., Misra, A., Saboo, B., Aravind, S. R., Hussain, A., Czupryniak, L., & Raz, I. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.12.032 · Cited by 60
Remission of Type 2 Diabetes with Very Low-Calorie Diets—A Narrative Review
Juray, S., Axen, K. V., & Trasino, S. E. (2021) · Nutrients · doi:10.3390/nu13062086 · Cited by 45
Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus
Blonde, L. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31823ea23e · Cited by 45
Control glucémico en pacientes con diabetes mellitus tipo 2 en España
Pérez, A., Mediavilla, J., Miñambres, I., & Alsina, D. G.-S. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.05.028 · Cited by 56
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0051-1 · Cited by 46
Remor, A. P., Matos, F., Ghisoni, K., da Silva, T. L., Eidt, G., Burigo, M. O., Bem, A. F. D., Silveira, P. C. L., de León, A., Sanchez, M. C., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.06.017 · Cited by 53
Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes
Plutzky, J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.014 · Cited by 46
Davidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
Management of dyslipidemia in people with type 2 diabetes mellitus
Dunn, F. L. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9132-6 · Cited by 46
Neugebauer, R. S., Schmittdiel, J. A., Zhu, Z., Rassen, J. A., Seeger, J. D., & Schneeweiß, S. (2014) · Statistics in Medicine · doi:10.1002/sim.6377 · Cited by 49
Neugebauer, R. S., FIREMAN, B. H., Roy, J., O’Connor, P. J., & Selby, J. V. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3253 · Cited by 46
Lim, N.-K., Park, S.-H., Choi, S.-J., Lee, K.-S., & Park, H. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1236 · Cited by 49
Zoungas, S., Chalmers, J. P., Kengne, A. P., Pillai, A., Billot, L., de Galan, B. E., Marre, M., Neal, B. C., Harrap, S. B., Poulter, N. R., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.05.012 · Cited by 51
Pepin, M. E., Schiano, C., Miceli, M., Benincasa, G., Mansueto, G., Grimaldi, V., Soricelli, A., Wende, A. R., & Claudio Napoli, A. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112485 · Cited by 43
Effect of metformin on outcomes of catheter ablation for atrial fibrillation
Deshmukh, A., Ghannam, M., Liang, J. J., Saeed, M., Cunnane, R. T., Ghanbari, H., Latchamsetty, R., Crawford, T. C., Batul, S. A., Chung, E. H., et al. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14954 · Cited by 46
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., Rozenberg, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1744 · Cited by 45
Wu, S., Shi, Y., Wang, C., Jia, Q., Zhang, N., Zhao, X., Liu, G., Wang, Y., Liu, L., Wang, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080690 · Cited by 47
Meier, M., & Hummel, M. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4808 · Cited by 45
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48
The case for intervention bias in the practice of medicine.
Foy, A., & Filippone, E. J. (2013) · Europe PMC (PubMed Central) · Cited by 43
Insulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Güallar, E., Banegas, J. R., Blasco‐Colmenares, E., Jimenez, F. J., Dallongeville, J., Halcox, J., Borghi, C., Massó-González, E. L., Tafalla, M., Perk, J., et al. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-704 · Cited by 55
Glycemic Control for Postoperative Pediatric Cardiac Patients
Preissig, C. M., Rigby, M. R., & Maher, K. (2009) · Pediatric Cardiology · doi:10.1007/s00246-009-9512-4 · Cited by 39
Elliott, M. D., Heitner, J. F., Kim, H., Wu, E., Parker, M. A., Lee, D. C., Kaufman, D. B., Bonow, R. O., Judd, R. M., & Kim, R. J. (2019) · Diabetes Care · doi:10.2337/dc18-2266 · Cited by 44
Self-citationLow triiodothyronine predicts mortality in critically ill patients
Kumar, K. V. S. H., Kapoor, U., Kalia, R., Chandra, N. S. A., Singh, P., & Nangia, R. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.109715 · Cited by 42
Gomez-Peralta, F., Escalada San Martín, F. J., Menéndez Torre, E., Mata Cases, M., Ferrer García, J. C., Ezkurra Loiola, P., Ávila Lachica, L., Fornos Pérez, J. A., Artola Menéndez, S., Álvarez-Guisasola, F., et al. (2018) · Endocrinología, Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 39
Luo, J., Khan, N. F., Manetti, T., Rose, J., Kaloghlian, A., Gadhe, B., JAIN, S. H., Gagne, J. J., & Kesselheim, A. S. (2019) · JAMA · doi:10.1001/jama.2018.21364 · Cited by 39
White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 40
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial
Siraj, E. S., Rubin, D. J., Riddle, M. C., Miller, M. E., Hsu, F., Ismail‐Beigi, F., Chen, S.-H., Ambrosius, W. T., Thomas, A., Bestermann, W. H., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0598 · Cited by 42
Self-citationMonnier, V. M., GENUTH, S. M., & Sell, D. R. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9702-2 · Cited by 44
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Salti, I., & on behalf of the Diabetes and Ramadan Study Group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02836.x · Cited by 38
Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition)
Dedov, I. I., Shestakova, M. V., Александров, А. А., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Кураева, Т. Л., Липатов, Д. В., Mayorov, A. Y., et al. (2013) · Diabetes Mellitus · doi:10.14341/dm20131s1-121 · Cited by 38
Glycemic control in the clinical management of diabetic patients
Mosca, A., Lapolla, A., & Gillery, P. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0594 · Cited by 41
The importance of the initial period of basal insulin titration in people with diabetes
Khunti, K., Giorgino, F., Berard, L., Mauricio, D., & Harris, S. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13946 · Cited by 41
Jiang, L., Shi, K., Guo, Y., Ren, Y., Li, Z., Xia, C., Li, L., Liu, X., Xie, L., Gao, Y., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01028-1 · Cited by 40
Winkler, G., Hídvégi, T., Vándorfi, G., Balogh, S., & Jermendy, G. (2013) · Medical Science Monitor · doi:10.12659/msm.883747 · Cited by 36
Kelly-Cobbs, A. I., Elgebaly, M. M., Li, W., & Ergul, A. (2010) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02230.x · Cited by 36
Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?
Meneghini, L. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.011 · Cited by 38
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Vázquez, L. A., Rodríguez, Á., Salvador, J., Ascaso, J. F., Petto, H., & Reviriego, J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-153 · Cited by 37
Doucet, J., Verny, C., Balkau, B., Scheen, A. J., & Bauduceau, B. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.003 · Cited by 36
Kuroda, N., Kusunoki, Y., Osugi, K., Ohigashi, M., Azuma, D., Ikeda, H., Makino, S., Otsuka, A., Tamada, D., Watanabe, N., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13336 · Cited by 43
Schwartz, S. S., & Kohl, B. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0468 · Cited by 40
The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
Tsang, M.-W. (2012) · ISRN Endocrinology · doi:10.5402/2012/478120 · Cited by 40
Targeted learning with daily EHR data
Sofrygin, O., Zhu, Z., Schmittdiel, J. A., Adams, A. S., Grant, R. W., van der Laan, M. J., & Neugebauer, R. (2019) · Statistics in Medicine · doi:10.1002/sim.8164 · Cited by 35
“Current recommendations specify target hemoglobin A1c of 7% for most patients [23, 39].”
BackgroundThe Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes
Somer, S., & Levy, A. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010287 · Cited by 38
Bertrand, O. F., Poirier, P., Rodés‐Cabau, J., Rinfret, S., Title, L. M., Džavík, V., Natarajan, M. K., Angel, J. G. D., Batalla, N., Alméras, N., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.005 · Cited by 34
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
Yamanouchi, T. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5838 · Cited by 38
Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Costantino, S., Paneni, F., & Cosentino, F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101606150407113644 · Cited by 38
Insulin therapy in critically ill patients
Ellahham, S. H. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s14203 · Cited by 35
Glycemic control in patients with type 2 diabetes mellitus in Spain
Pérez, A., Mediavilla, J., Miñambres, I., & González-Segura, D. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.05.007 · Cited by 35
Confronting The Urgent Challenge Of Diabetes: An Overview
FRADKIN, J. E. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1150 · Cited by 36
Lipska, K. J., Wang, Y., Kosiborod, M., Masoudi, F. A., Havranek, E. P., Krumholz, H. M., & Inzucchi, S. E. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.887620 · Cited by 34
Self-citationElevated hemoglobin A1c is associated with readmission but not complications
Engoren, M., Schwann, T. A., & Habib, R. H. (2014) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/0218492313515895 · Cited by 34
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 37
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.